Business Overview
A US-based pharmaceutical company needed to analyze the performance of its drugs against competitors to identify growth opportunities and improve market access. The company’s business users were dependent on vendor and IT teams for custom reports, which hindered their ability to conduct ad-hoc analysis and get timely insights. They needed a self-service business intelligence (BI) platform to empower them to analyze key metrics on their own.
Business Challenges
The company faced several key challenges due to its reliance on external teams and legacy reporting methods. The business users were unable to perform real-time analysis on their own, which led to delays in critical decision-making. The process for generating reports was rigid and not adaptable to changing business needs. Specifically, the problems included:
- Limited Self-Service Analytics: Business users could not independently create additional analysis or custom reports, forcing them to depend on vendor and IT teams for every new request.
- Delayed Insights: The manual process for obtaining and analyzing data for market access and drug performance led to slow turnaround times, hindering proactive decision-making.
- Lack of Granular Analysis: There was a need to deeply analyze performance across multiple dimensions, such as Drug Strength, Plan Type, Payer, and HCP specialties, which was not easily achievable with their existing methods.
- Inefficient Benchmarking: The process for benchmarking drug access and prescription patterns was cumbersome and did not provide the required level of detail.
Approach and Key Metrics
To address these requirements, a comprehensive BI solution was developed using QlikView. This approach involved aggregating and linking data from multiple sources to create a unified analytical platform. The main data source was rolling 24-month prescription (Rx) data from IMS. This was integrated with other key data sources for HCPs (ZIP codes, specialties, decile ratings), national and regional accounts (payers), formulary access (Preferred/Non-Preferred/Covered/Not Covered), and regional hierarchy structures.
The solution enabled business users to analyze several key metrics:
- Rx Volume & Share: Analyzing prescription volume and market share percentage for each drug (TRx/NRx).
- Growth Trends: Measuring Rx volume and share growth percentages based on various analysis periods.
- Contribution Analysis: Assessing Rx contribution by top national and regional accounts.
- Formulary & HCP Access: Analyzing brand, plan type, and national account-wise formulary access percentages, and using pull-through analysis to monitor top plans, PBMs, and HCPs.
Benefits Obtained
The implementation of the QlikView dashboard provided significant benefits, transforming the way business users accessed and analyzed drug performance data.
- Timely Insights: Users could track drug performance across multiple time periods, including month-over-month (MvM), 3v3, 6v6, 12v12, and YTD.
- Advanced Analytics: The tool provided advanced analysis options to track drug performance based on key parameters such as formulary grouping, HCP specialty, and plan type.
- Self-Service Capabilities: Users gained the ability to create and pull ad-hoc reports for their specific analysis requirements, reducing reliance on IT and vendors.
- Ease of Use: A user-friendly interface made it simple to compare brands against each other and against the overall market.
- Secure Data Access: The solution included built-in data restrictions based on market and regional hierarchies, ensuring data privacy and compliance.